syn120
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02258152)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 6 (5-HT6) receptorINHIBITOR
HTR6 inhibitor
Serotonin receptor 2a and 2b (5HT2A and 5HT2B) inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- syn120
- syn120
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02258152 | Phase 2 | Dec 1, 2014 | Biotie Therapies, Harvard University, Michael J. Fox Foundation for Parkinson's Research |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biotie Therapies | For profit | 1 | 1 | 1 | 2014 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Michael J. Fox Foundation for Parkinson's Research | Academic/Hospital | 1 | 0 | 1 | 2014 |
3 organizations
Page 1 / 1